Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
NEW YORK, Nov. 29, 2016 -- Ovid Therapeutics, a privately-held biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced its participation in two upcoming investor conferences:
- Citi 2016 Global Healthcare Conference
Members of the Company’s management team will participate in one-on-one meetings with investors on Wednesday, December 7, 2016, at the Lotte Palace Hotel in New York, NY.
- BMO Capital Markets 2016 Prescription for Success Healthcare Conference
Yaron Werber, M.D., chief business and financial officer of Ovid, will present on Wednesday, December 14, 2016, at 4:40 p.m. ET at the InterContinental Barclay Hotel in New York, NY.
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a privately held, New York-based, biopharmaceutical company committed to transforming the lives of patients with orphan diseases of the brain. Ovid focuses on patients and their unmet medical needs. Using the significant operational, product development, and business development experience of its management team, Ovid aims to become a leading neurology company, with multiple products and a rich pipeline, coupled with compelling research and development. Ovid has raised $80M in financings led by Fidelity Management and Research Company and including Cowen Private Investments, Sanofi-Genzyme BioVentures, Tekla Capital Management, Sphera Global Healthcare Fund, Jennison Associates, Redmile Group, DoubleLine Equity Healthcare Fund, and Cormorant Asset Management, as well as additional blue chip mutual funds and leading life sciences investors.
Contacts Investors: Burns McClellan Steve Klass, 212-213-0006 [email protected] Media: Pure Communications, Inc. Katie Engleman, 910-509-3977 [email protected]
